I f prostate cancer has spread to other areas of your body, your doctor may recommend androgen deprivation therapy (ADT), which halts the production of androgen hormones, especially testosterone.

Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results. Concomitant G-CSF use in maintaining an ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of international research on androgen deprivation therapy (ADT) for prostate cancer ...

New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...

If you’ve been diagnosed with advanced prostate cancer, there’s a good chance you’ll receive androgen deprivation therapy (ADT) at some point, as ADT is a mainstay of prostate cancer treatment. It ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Perioperative treatment with apalutamide and androgen deprivation therapy (ADT) is beneficial for patients with high-risk ...

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first ...

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer. The combination of Nubeqa (darolutamide) ...

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...